Selected publication milestones, not an exhaustive history or discovery priority claim.
1966 — 1966 prolonged randomized Veterans feeding documents lipid lowering and tissue-linoleic enrichment; this examined report does not supply coronary-event outcomes. Original PMID5900208.
1979 — 1979 Finnish hospital-period male coronary findings are favourable under controlled dietary reversal, with allocation and period confounding retained. Original PMID393644.
1983 — 1983 the Finnish women's companion reports a nonsignificant coronary difference despite lipid lowering, illustrating endpoint and context limits. Original PMID6840954.
1989 — 1989 the Minnesotaoriginal clinical report finds no overall cardiovascular-event or mortality benefit despite cholesterol lowering. Original PMID2643423.
1994 — 1994 Lyon demonstrates clinical benefit from a mixed Mediterranean dietary pattern, without isolating an LA-rich oil component. Original PMID7911176.
2012 — 2012 an isocaloric vegetableomega6-versus-butter experiment finds no proinflammatory signal and lower liver fat, with biomarkers kept separate from coronary events. Original PMID22492369.
2013 — 2013 Sydneyrecovered participant data reveal an adverse coronary-mortality contrast under a highLAhistorical intervention; the meta-analysis is counted separately from original-data credit. Original PMID23386268.
2015 — 2015 DIVASimproves lipid markers but not its primary vascular outcome; estimated mortality benefit remains an extrapolation. Original PMID26016869.
2015 — 2015 long-term dietary substitution models favour PUFAand whole-grain replacement over refined carbohydrates, while allocation remains observational. Original PMID26429077.
2016 — 2016 the recovered Minnesotaanalysis adds original longitudinal and partial-autopsy information to the same parent trial; the clinical null is not a new independent trial. Original PMID27071971.
2019 — 2019 FADSDIETreports genotype-dependent short marker responses, requiring prospective controlled clinical validation. Original PMID30624587.
2021 — 2021 a large carnivore-maintainer survey records perceived benefits and lipid uncertainty without a long-term cardiovascular comparison. Original PMID34934897.
2021 — 2021 fatty-acid genetic analysis supports selected linoleic-CAD estimates, with endogenous-metabolism scope retained. Original PMID33924952.
2022 — 2022 a largerPUFAGWAS/MRanalysis finds inconsistent cardiovascular estimates and lipoprotein/FADSlocus sensitivity. Original PMID35692035.
2025 — 2025 a small German carnivorepre/post study reports perceived benefits and increased LDLrather than adjudicated clinical superiority. Original PMID40385902.
2025 — 2025 observational and genetic analyses report sex-specificomega6-CADsupport, without equating plasma percentages to an allocated oil substitution. Original PMID40199060.
Accessible primary-result verification of the old VA, Oslo Diet-Heart, MRCsoybean and Rose clinical studies, with actual composition and endpoint hierarchy
Modern long-term allocated oil-swap coronary-event trials with contemporary prevention care
Distinct causal identification of dietary LA-rich oil exposure versus circulating fatty-acid metabolism and shared FADSor lipoprotein instrument pathways
Usual-intake inflammatory coronary harm versus high-dose historical margarine, repeated heating and short biomarker changes
Food-matrix and comparator effects, including saturated-fat sources, refined carbohydrate replacement and mixedomega3/omega6oils
Defined carnivore patterns assessed against an active balanced comparator on actual cardiovascular events rather than maintainer surveys
Randomize adults with prospectively defined coronary risk to isocaloric replacement of a specified saturated-fat food source with a chemically characterized LA-rich oil, versus retained saturated-fat food and an independently specified unsaturated-oil comparator. Prespecify adjudicated fatal and nonfatal coronary events over multiple years, achieved dietary intake, trans-fat exposure, background omega3, medication stability and analysis. Use LDL/apoBand inflammatory measurements as candidate mediators, not as substituted clinical outcomes.